Markus Goebel
Biotech & Medtech consulting
Einsiedeln, Schwyz
Invests in
Education
Lists including Markus
Investments
Work Experience
2024
Director
2024
OSE Immunotherapeutics is an integrated biotechnology company dedicated to developing First-In-Class Immunotherapies in Immuno-Inflammation (I&I) and Immuno-Oncology (I-O).
2022
Expert
2022
2022
Director
2022
hemotune AG is a pioneering Swiss biotech company based on nanoengineered magnetic beads and its breakthrough technology platform with multiple application possibilities. It has recently closed a CHF 14m Series B to advance the lead program into the clinic.
Founder & CEO
2019
Biotech and MedTech consulting
2020 - 2020
Director
2020 - 2020
HAYA Therapeutics is a Swiss-based pre-clinical early stage biopharmaceutical company dedicated to treating fibrotic diseases through the discovery and development of innovative targeted first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
2004 - 2019
Managing Director
2004 - 2019
• Managing Director Novartis Venture Fund (NVF) 2004-2019 (US & EU) • Investments: Sirtris (sirtuins), FoldRx (protein misfolding), Locus (in-silico drug design), Trellis (human MAbs), LigoCyte (vaccines), Visiogen (IOL device; co-lead), Ra Pharma (cyclic peptides), Sorbent (polymer for CHF), Intellikine (PI3K/mTOR pathway), Avila (covalent sm; co-lead), eFFECTOR (protein translation), merganser (hepcidin mimetics), AlloCyte (LFA-1 inhibitors), Expansion (repeat mRNA; co-lead), Ribon (monoPARPs) • Key investment contributions: Ablation Frontiers (AF device), Proteostasis (protein networks), Sonitus (hearing device) • Exits: IPO: Sirtris, Proteostasis, Ra Pharma; M&A: FoldRx (Pfizer), Ablation Frontiers (Medtronic), Visiogen (Abbott), Intellikine (Takeda), Avila (Celgene), LigoCyte (Takeda)
2000 - 2004
Head Pharma Corporate M&A
2002 - 2004
Acquisitions and divestments in and out of Novartis AG
Head Nervous System BD&L Pharma
2000 - 2002
Licensing options for Novartis Pharma in Nervous System
1992 - 1999
Several Marketing & Strategy positions incl. an alliance with Amgen
1992 - 1999
Head of Strategic Portfolio Management & Life Cycle Planning Pharma Senior Business Analyst Strategic Unit Pharma International Medical & Registration Manager Neupogen® (in co-operation with AMGEN)
1990 - 1992
Medical Manager Oncology & Medical Science
1990 - 1992